CAR-T cell therapy for autoimmune diseases
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with one of the autoimmune diseases listed: SLE, systemic sclerosis, ANCA vasculitis, inflammatory myopathy, or Sjögren's syndrome.
- Your disease is active (moderate to severe), and standard treatments haven't worked well enough.
- Your liver, kidneys, and blood counts are within a safe range (your doctor can check).
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
- You have not had a serious infection in the last 2 weeks, and you do not have active hepatitis B, C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like lupus, scleroderma, vasculitis, muscle inflammation, and Sjögren's syndrome that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and reduce the B cells driving your disease.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.